Literature DB >> 25138723

GMP-compliant human adipose tissue-derived mesenchymal stem cells for cellular therapy.

Hamid-Reza Aghayan1, Parisa Goodarzi, Babak Arjmand.   

Abstract

Stem cells, which can be derived from different sources, demonstrate promising therapeutic evidences for cellular therapies. Among various types of stem cell, mesenchymal stem cells are one of the most common stem cells that are used in cellular therapy. Human subcutaneous adipose tissue provides an easy accessible source of mesenchymal stem cells with some considerable advantages. Accordingly, various preclinical and clinical investigations have shown enormous potential of adipose-derived stromal cells in regenerative medicine. Consequently, increasing clinical applications of these cells has elucidated the importance of safety concerns regarding clinical transplantation. Therefore, clinical-grade preparation of adipose-derived stromal cells in accordance with current good manufacturing practice guidelines is an essential part of their clinical applications to ensure the safety, quality, characteristics, and identity of cell products. Additionally, GMP-compliant cell manufacturing involves several issues to provide a quality assurance system during translation from the basic stem cell sciences into clinical investigations and applications. On the other hand, advanced cellular therapy requires extensive validation, process control, and documentation. It also evidently elucidates the critical importance of production methods and probable risks. Therefore, implementation of a quality management and assurance system in accordance with GMP guidelines can greatly reduce these risks particularly in the higher-risk category or "more than minimally manipulated" products.

Entities:  

Mesh:

Year:  2015        PMID: 25138723     DOI: 10.1007/7651_2014_112

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  7 in total

1.  Novel flow cytometric analysis of the blood-brain barrier.

Authors:  Dionna W Williams; Lydia Tesfa; Joan W Berman
Journal:  Cytometry A       Date:  2015-04-30       Impact factor: 4.355

Review 2.  Metabolomics and Cell Therapy in Diabetes Mellitus.

Authors:  Bagher Larijani; Parisa Goodarzi; Moloud Payab; Sepideh Alavi-Moghadam; Fakher Rahim; Nikoo Bana; Mina Abedi; Maryam Arabi; Hossein Adibi; Kambiz Gilany; Babak Arjmand
Journal:  Int J Mol Cell Med       Date:  2019-05-30

Review 3.  Auxiliary role of mesenchymal stem cells as regenerative medicine soldiers to attenuate inflammatory processes of severe acute respiratory infections caused by COVID-19.

Authors:  Peyvand Parhizkar Roudsari; Sepideh Alavi-Moghadam; Moloud Payab; Forough Azam Sayahpour; Hamid Reza Aghayan; Parisa Goodarzi; Fereshteh Mohamadi-Jahani; Bagher Larijani; Babak Arjmand
Journal:  Cell Tissue Bank       Date:  2020-06-25       Impact factor: 1.522

Review 4.  Metabolomics Analysis of Mesenchymal Stem Cells.

Authors:  Parisa Goodarzi; Sepideh Alavi-Moghadam; Moloud Payab; Bagher Larijani; Fakher Rahim; Kambiz Gilany; Nikoo Bana; Akram Tayanloo-Beik; Najmeh Foroughi Heravani; Mahdieh Hadavandkhani; Babak Arjmand
Journal:  Int J Mol Cell Med       Date:  2019-06-20

5.  Xeno-free workflow exhibits comparable efficiency and quality of keratinocytes isolated from human skin biopsies.

Authors:  Cathrine Lagerwall; Hady Shahin; Sallam Abdallah; Ingrid Steinvall; Moustafa Elmasry; Folke Sjöberg; Ahmed T El-Serafi
Journal:  Regen Ther       Date:  2021-09-29       Impact factor: 3.419

6.  Validation of a novel animal model for sciatic nerve repair with an adipose-derived stem cell loaded fibrin conduit.

Authors:  Maximilian M Saller; Rosa-Eva Huettl; Julius M Mayer; Annette Feuchtinger; Christian Krug; Thomas Holzbach; Elias Volkmer
Journal:  Neural Regen Res       Date:  2018-05       Impact factor: 5.135

7.  Co-transplantation of Human Fetal Mesenchymal and Hematopoietic Stem Cells in Type 1 Diabetic Mice Model.

Authors:  Babak Arjmand; Parisa Goodarzi; Hamid Reza Aghayan; Moloud Payab; Fakher Rahim; Sepideh Alavi-Moghadam; Fereshteh Mohamadi-Jahani; Bagher Larijani
Journal:  Front Endocrinol (Lausanne)       Date:  2019-11-06       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.